Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.779 USD | +9.00% | +13.91% | +11.18% |
Apr. 25 | OncoCyte Corporation announced that it has received $15.807655 million in funding | CI |
Apr. 16 | Broadwood Capital, Inc. Engages with OncoCyte Corporation | CI |
Summary
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.18% | 34.08M | D+ | ||
-1.86% | 104B | B+ | ||
+6.78% | 97.47B | B+ | ||
+5.71% | 22.25B | B | ||
-12.89% | 21.68B | B+ | ||
-9.70% | 18.2B | A- | ||
-39.98% | 17.02B | A- | ||
-10.25% | 16.36B | B | ||
+6.51% | 14.39B | C+ | ||
+35.21% | 12.37B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- OCX Stock
- Ratings OncoCyte Corporation